Andries M Bergman
Andries M Bergman
Andere namenAndries Bergman, Andre Bergman, Andre M Bergman
Medical Oncologist and Research Group Leader, Netherlands Cancer Institute
Geverifieerd e-mailadres voor nki.nl
Geciteerd door
Geciteerd door
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
Determinants of resistance to 2′, 2′-difluorodeoxycytidine (gemcitabine)
AM Bergman, HM Pinedo, GJ Peters
Drug resistance updates 5 (1), 19-33, 2002
Interaction between cisplatin and gemcitabine in vitro and in vivo.
GJ Peters, AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, ...
Seminars in oncology 22 (4 Suppl 11), 72-79, 1995
Synergistic interaction between cisplatin and gemcitabine in vitro.
AM Bergman, VW Ruiz van Haperen, G Veerman, CM Kuiper, GJ Peters
Clinical cancer research: an official journal of the American Association …, 1996
Basis for effective combination cancer chemotherapy with antimetabolites
GJ Peters, CL Van der Wilt, CJA Van Moorsel, JR Kroep, AM Bergman, ...
Pharmacology & therapeutics 87 (2-3), 227-253, 2000
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines
CJA Van Moorsel, HM Pinedo, G Veerman, AM Bergman, CM Kuiper, ...
British journal of cancer 80 (7), 981-990, 1999
In vivo Induction of Resistance to Gemcitabine Results in Increased Expression of Ribonucleotide Reductase Subunit M1 as the Major Determinant
AM Bergman, PP Eijk, VWT Ruiz van Haperen, K Smid, G Veerman, ...
Cancer research 65 (20), 9510-9516, 2005
Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
Journal of Clinical Oncology 34 (25), 3005-3013, 2016
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines
AM Bergman, HM Pinedo, I Talianidis, G Veerman, WJP Loves, ...
British journal of cancer 88 (12), 1963-1970, 2003
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone …
S Badrising, V van der Noort, IM van Oort, HP van den Berg, M Los, ...
Cancer 120 (7), 968-975, 2014
Combination chemotherapy studies with gemcitabine.
CJ Van Moorsel, G Veerman, AM Bergman, A Guechev, JB Vermorken, ...
Seminars in oncology 24 (2 Suppl 7), S7-17, 1997
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
LF van Dessel, J van Riet, M Smits, Y Zhu, P Hamberg, ...
Nature communications 10 (1), 1-13, 2019
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines
AM Bergman, CM Kuiper, DA Voorn, EM Comijn, F Myhren, ML Sandvold, ...
Biochemical pharmacology 67 (3), 503-511, 2004
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ...
Nature genetics 52 (8), 790-799, 2020
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
GJ Peters, VW Ruiz van Haperen, AM Bergman, G Veerman, ...
Seminars in oncology 23 (5 Suppl 10), 16-24, 1996
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
AM Bergman, AD Adema, J Balzarini, S Bruheim, I Fichtner, P Noordhuis, ...
Investigational new drugs 29 (3), 456-466, 2011
Integrative epigenetic taxonomy of primary prostate cancer
S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ...
Nature communications 9 (1), 1-12, 2018
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label …
KN Chi, CS Higano, B Blumenstein, JM Ferrero, J Reeves, S Feyerabend, ...
The lancet oncology 18 (4), 473-485, 2017
Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of …
K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, ...
European urology 78 (6), 822-830, 2020
Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis
S Stelloo, E Nevedomskaya, Y Kim, L Hoekman, OB Bleijerveld, T Mirza, ...
Oncogene 37 (3), 313-322, 2018
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20